Targeted at both R&D and production facilities, the synthesizer is suitable for organizations requiring large quantities of unique DNA and RNA to develop diagnostic and therapeutic applications for various viruses, diseases, and conditions, according to the company.

The Dr. Oligo 768XLc DNA RNA Synthesizer. Image Courtesy of Biolytic.

It can be used to support applications such as gene synthesis, genetic diagnostic test kits, reverse transcription polymerase chain reaction, siRNA/RNAi, miRNA, CRISPR Cas9, anti-sense treatments, and DNA/RNA sequencing. It also can be utilized in broader areas, including evolutionary history, forensics, immunotherapy, diagnostic and therapeutic research, high-throughput screening, modified oligos, mixed backbones, locked nucleic acids, and the visual detection of virus RNA such as COVID-19 following reverse transcription loop-mediated isothermal amplification with DNA primers, the firm said.

Biolytic said that its patent-pending system optimizes reagent use by thoroughly mixing the entire volume of reagent delivered to each reaction well. It also achieves near 100% reaction efficiency, the company said. In other features, Dr. Oligo 768XLc's patent-pending nodule system dispenses 16 nozzles simultaneously, reducing maintenance and operating costs as well as helping to speed up synthesis time, according to the vendor.

Dr. Oligo 768XLc comes with fully tested protocols and initial 384-well synthesis media from 2 to 100 nmol per well to provide turn-key synthesis beginnings, the company said. Trityl collection, oligo desalting, and elution capabilities are also available as options.